News from Austria and Switzerland

Ah I found what had given me the impression Jonathan has suggested IVIG might have marginal benefits.
The situation for IVIg in ME/CFS is probably quite well documented now. As for most other conditions it has been tried for there are small trials suggesting some, but not very major or consistent, benefit. IVIg was never a very practical approach and from a theoretical standpoint is likely to do just that - having some, but not very major, consistent or sustained benefit. To be honest I think we know enough to say that if we think there is a theoretical basis for something of that sort it would be more sensible to manufacture a 'decoy' monoclonal antibody with an Fc binding site but no functional antigen binding site.
Click to expand...

Jonathan Edwards

Preprint Post in thread 'A Proposed Mechanism for ME/CFS Invoking Macrophage Fc-gamma-RI and Interferon Gamma, 2025, Edwards, Cambridge and Cliff'

ME/CFS Skeptic said:
Currently the hypothesis seems quite flexible with lots of connections not yet filled in yet. I wonder if there are any tests, observations or experiments that would not fit or refute the hypothesis?
Click to expand...

There are observations that will test various aspects. The most obvious is a large scale GWAS study to look at the risk profile. We ill see how things pan out!

ME/CFS Skeptic said:
Also interested in the sentence about intravenous immunoglobulin because quite a lot of patients are still experimenting with this, so there is likely some data on it. I assume it would need to taken repeatedly in order for...
Click to expand...
  • Like
 
I know several people who have tried it. As already mentioned by @Utsikt, this therapy is very popular in Germany and Austria, for whatever reason. I believe the study that initially triggered this interest was the following one:
SNT Gatchaman

Trial Report Thread 'Successful Subcutaneous Immunoglobulin Therapy in a Case Series of Patients With [ME/CFS], 2024, Sjogren, Bragée, Britton.'

Successful Subcutaneous Immunoglobulin Therapy in a Case Series of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Per Sjogren; Bjorn Bragée; Sven Britton

PURPOSE
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) remains an enigma with no curable treatment options at hand. Although patients with ME/CFS are a heterogeneous group, a large proportion of patients present with an infection-driven symptomatology, making them potential responders to immunologic treatments, such as immunoglobulin (IG). Previous studies on IG treatment in patients with ME/CFS...
  • Like
The comments say it all.
However, no one has actually benefited from it.
 
The only study of IVIG with very good methodology (double blind placebo controlled randomised) found a null result.

It‘s fair to criticise the study for being old. But the diagnostic criteria they used is actually rather robust for that time.

I don‘t think another RCT would be a bad thing, but in the mean time I think the best evidence we have says it doesn’t help.

Yann04

Trial Report Thread 'Intravenous Immunoglobulin is Ineffective in the Treatment of Patients with Chronic Fatigue Syndrome, 1997, Vollmer-Conna et al'

Intravenous Immunoglobulin is Ineffective in the Treatment of Patients with Chronic Fatigue Syndrome

Vollmer-Conna, Ute; Hickie, Ian; Hadzi-Pavlovic, Dusan; Tymms, Kathie; Wakefield, Denis; Dwyer, John; Lloyd, Andrew

Abstract

PURPOSE: To determine whether the reported therapeutic benefit of intravenous immunoglobulin in patients with chronic fatigue syndrome (CFS) is dose dependent.
PATIENTS AND METHODS: Ninety-nine adult patients, who fulfilled diagnostic criteria for CFS, participated in this double-blind, randomized, and placebo-controlled trial. Patients received...
  • Like
 
Last edited:

900-word article about Dejan Lauber, a young man with ME/CFS, who has also been featured in this moving documentary from 2022 by SRF, the public Swiss TV broadcaster.

AI Summary:

Attending Family Gatherings by Robot: “How I Can Escape Isolation from Time to Time”​

Once a globetrotter, Dejan Lauber is now confined to his two-room apartment. A robot, however, gives him access to the outside world.​

Dejan Lauber, 34, developed ME/CFS after a civilian service assignment in Madagascar. For years he has been unable to leave his apartment and lives with constant physical exhaustion, carefully rationing his limited energy. His symptoms include burning muscles, severe fatigue and shortness of breath, and overexertion can worsen his condition. Once adventurous and active, his daily life is now confined to his two-room apartment, where even short visits are only possible on good days.

To stay connected with the outside world and his family, Lauber uses a small robot that he controls with his phone. The robot visits his father, joins family gatherings, plays games with relatives and allows shared moments despite physical separation. Through the robot, Lauber can see, hear and explore his surroundings and occasionally take part in activities such as being placed on a horse, a car roof or a floating mattress at sea. He says this helps him escape isolation from time to time.

Lauber receives a full disability pension, and his parents and relatives support him daily with meals, shopping and household tasks. With family and friends, he also builds robots for other chronically ill people through the Botkins Charity Project, which has already distributed several devices. He earns no money from the project and says it gives his situation a sense of meaning.
Click to expand...
 
kontrast.at

Datenrecherche: Wer sich mehrmals mit Corona infiziert, hat auch heute noch Risiko für Spätfolgen

Fünf Jahre sind seit den ersten Corona-Fällen 2020 vergangen und vielerorts hört man, Corona sei mittlerweile wie ein harmloser Schnupfen. Doch internationale Langzeitstudien zu den sogenannten “Post-Akuten-Infektions-Syndromen“ (PAIS), zu denen auch Erkrankungen wie Long Covid und ME/CFS...
kontrast.at kontrast.at

2500-word article by
Jana Winter has been a member of the association Long Covid Austria since early 2025. She works at the academic intersection of ethics, philosophy, and technology. She has published, among others, with the Austrian Academy of Sciences and at Tohoku University in Japan.
Click to expand...

AI Summary:
Data Research: Repeated COVID-19 Infections Still Carry a Risk of Long-Term Consequences

Five years after the first COVID-19 cases in 2020, the pandemic is often portrayed as a completed crisis. However, international long-term studies on post-acute infectious syndromes (PAIS), including Long Covid and ME/CFS, suggest ongoing and serious health risks. Some researchers describe the current situation as a “pandemic after the pandemic,” referring to widespread long-term consequences rather than a new pathogen.

Long Covid Is Widespread, Not a Niche Condition

A 2024 publication estimates around 400 million people worldwide are affected by COVID-19 long-term conditions, with a global prevalence of 36% among infected individuals. Austria, Germany, and the United States report high numbers, though Austrian figures are based on estimates due to missing systematic data and limited diagnostic recognition.

Repeated Infections Increase Long-Term Risks

Studies show that the risk of Long Covid and other follow-up conditions increases with each reinfection. A second infection raises Long Covid risk to around 25%, and a third to 38%. Reinfections also increase risks for cardiovascular disease, diabetes, organ damage, and autoimmune conditions. New data indicate that reinfection raises Long Covid risk by 35%, even in previously unaffected individuals.

Children and Adolescents Are Particularly Affected

Large studies reveal that a second infection doubles Long Covid risk in people under 21. Children and adolescents show increased risks of organ damage, mental health disorders, and new chronic diseases, and should be monitored for up to two years after infection.

Chronic Disease, Costs, and Prevention

About half of Long Covid cases persist beyond two years, often becoming chronic conditions such as ME/CFS. Economic costs are substantial, reaching billions annually. Experts emphasize prevention, research, and specialized care as key responses.
Click to expand...
 
You must log in or register to reply here.
Back
Top Bottom